IN8bio (NASDAQ:INAB) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS

IN8bio (NASDAQ:INAB) posted its quarterly earnings results on Thursday. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.10, FiscalAI reports.

IN8bio Trading Up 11.6%

Shares of INAB traded up $0.10 during trading hours on Friday, reaching $0.93. The company had a trading volume of 33,376 shares, compared to its average volume of 39,109. IN8bio has a 12-month low of $0.80 and a 12-month high of $2.73. The firm has a 50 day simple moving average of $1.13 and a 200-day simple moving average of $1.42. The company has a market capitalization of $9.14 million, a price-to-earnings ratio of -0.92 and a beta of 0.27.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IN8bio in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold”.

IN8bio Company Profile

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.